Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 3/20 | 0.39 |
| ▸ | TYMS | P04818 | 4/20 | 0.34 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | UMPS | P11172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883825 | 1.00 | HPRT1 (0.39) | HPRT1TYMSDNPH1FBP1UMPS | |
| SCHEMBL17484473 | 0.89 | P2RY2 (0.37) | — | |
| SCHEMBL16102809 | 0.88 | P2RY2 (0.36) | — | |
| SCHEMBL16629545 | 0.83 | GAA (0.33) | — | |
| SCHEMBL16102808 | 0.83 | P2RY2 (0.36) | — | |
| SCHEMBL16130071 | 0.82 | P2RY14 (0.31) | — | |
| SCHEMBL16629496 | 0.80 | GAA (0.37) | — | |
| SCHEMBL16130127 | 0.80 | GAA (0.37) | — | |
| SCHEMBL21275612 | 0.80 | GAA (0.37) | — | |
| SCHEMBL16098132 | 0.80 | GAA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192753-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RANA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-10822368-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3301102-B1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190263850-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-2970351-B1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20160031928-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2014152513-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822368-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | RNMT, RNGTT, NSUN3 | HPRT1 135/4885TYMS 73/4885DNPH1 1370/4885 |
| US-20190263850-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | HPRT1 129/4885TYMS 67/4885DNPH1 1349/4885 |
| US-20230192753-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | HPRT1 129/4885TYMS 67/4885DNPH1 1349/4885 |
| US-20160031928-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | HPRT1 129/4885TYMS 67/4885DNPH1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.